LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

mRNA Test Screens for Multiple Cancers from Single Blood Sample

By LabMedica International staff writers
Posted on 27 May 2022
Image: Aristotle blood test detects molecular signatures of multiple cancers from single blood sample (Photo courtesy of StageZero Life Sciences)
Image: Aristotle blood test detects molecular signatures of multiple cancers from single blood sample (Photo courtesy of StageZero Life Sciences)

Almost 50% of people are diagnosed with cancer in the later stages when the outcomes are poor. A late stage cancer diagnosis can be attributed to many factors such as postponing cancer screening, the fact that symptoms often don't appear until cancer has progressed, or a lack of convenient screening options. Now, a new blood test that detects the molecular signatures of multiple cancers from a single sample of blood could help find cancer earlier.

StageZero Life Sciences, Ltd. (Richmond Hill, Canada) next generation test, Aristotle, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Aristotle test works by interrogating mRNA from a sample of whole blood and detecting gene expression profiles indicative of specific cancers. It screens for the molecular signatures associated with multiple, individual cancers, including breast, ovarian, endometrial, colorectal, liver, stomach, prostate, and others.

"Far too often, cancer is diagnosed and treated at a late stage, which can dramatically decrease survival rates and affect patients' quality of life," said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "This is more of an issue now, with the COVID-19 pandemic having significantly reduced patient/physician interactions. We are seeing a wave of late-stage diagnoses" he continued. "Use of a blood test that looks for the most common forms of treatable cancers can help reduce the risk of developing advanced-stage cancer through early detection. We believe that providing an opportunity to find cancer early will facilitate more favorable outcomes."

Related Links:
StageZero Life Sciences, Ltd. 

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more